The earnings call presented a balanced view with significant revenue growth and successful R&D milestones on one hand, and challenges such as project discontinuation and potential future tariff impacts on the other.

Company Guidance -

Q3 2025

During the call, the company provided detailed guidance and updates on its financial performance and strategic initiatives for the second quarter of fiscal year 2025. Revenue increased by 4.6% compared to the previous year, reaching JPY 578.5 billion, with operating profit up by 3.5% at JPY 272 billion. Net income also saw a rise of 2.1%. The growth was primarily driven by a 5.3% increase in sales, with domestic sales up by 2.8% and overseas sales up by 7.3%. However, domestic sales were negatively impacted by NHI drug price revisions and the penetration of generics, while new products like Phesgo and Vabysmo contributed positively. The company highlighted its R&D progress, including the successful Phase III trial of orforglipron and the initiation of new trials for projects like AUBE00. Additionally, a significant investment of JPY 80 billion was announced for a new research building to enhance manufacturing capabilities. The company also addressed the discontinuation of five early-stage projects to better focus resources on high-priority areas, aiming to achieve the goals set in their TOP I 2030 strategy.

Increased Revenue and Profit

Revenue increased by 4.6% to JPY 578.5 billion. Operating profit increased by 3.5%, and net income increased by 2.1% compared to the previous year.

Successful R&D Milestones

The global Phase III trial for orforglipron showed success, and new projects such as MINT91 and AUBE00 began Phase I trials.

Strong Sales Performance

Domestic sales increased by 2.8%, and overseas sales increased by 7.3%. Actemra exports were particularly strong.

New Investments

An investment of JPY 80 billion to build a new research building at the Ukima site, focusing on environmentally friendly equipment.

Chugai Pharmaceutical Co (JP:4519) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

JP:4519 Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 24, 2025	2025 (Q3)	73.45 / -	66.55	―	―	―
Jul 24, 2025	2025 (Q2)	74.09 / 57.83	67.98	-14.93% (-10.15)
Apr 24, 2025	2025 (Q1)	50.97 / 59.09	45.22	30.67% (+13.87)
Jan 30, 2025	2024 (Q4)	58.98 / 55.64	55.434	0.37% (+0.21)
Oct 25, 2024	2024 (Q3)	60.40 / 66.55	47.15	41.15% (+19.40)		―
Jul 25, 2024	2024 (Q2)	54.06 / 67.98	50.57	34.43% (+17.41)
Apr 24, 2024	2024 (Q1)	47.26 / 45.22	44.68	1.21% (+0.54)		―
Feb 01, 2024	2023 (Q4)	50.77 / 55.43	62.29	-11.01% (-6.86)		―
Oct 24, 2023	2023 (Q3)	48.90 / 47.15	41.21	14.41% (+5.94)		―
Jul 27, 2023	2023 (Q2)	41.46 / 50.57	44	14.93% (+6.57)		―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

JP:4519 Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jul 24, 2025	¥7117.00	¥7238.00	+1.70%
Apr 24, 2025	¥8058.93	¥8114.99	+0.70%
Jan 30, 2025	¥6274.83	¥6261.06	-0.22%
Oct 25, 2024	¥6771.54	¥6700.33	-1.05%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Chugai Pharmaceutical Co Ltd (JP:4519) report earnings?

Chugai Pharmaceutical Co Ltd (JP:4519) is schdueled to report earning on Oct 24, 2025, Before Open (Confirmed).

What is Chugai Pharmaceutical Co Ltd (JP:4519) earnings time?

Chugai Pharmaceutical Co Ltd (JP:4519) earnings time is at Oct 24, 2025, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is the P/E ratio of Chugai Pharmaceutical Co Ltd stock?

The P/E ratio of Chugai Pharmaceutical Co is N/A.

What is JP:4519 EPS forecast?

JP:4519 EPS forecast for the fiscal quarter 2025 (Q3) is 73.45.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing